RTX vs TRDA · P/E 36, rev $88.60B vs P/E 12, rev $210.8M
RTX Corporation (RTX) versus Entrada Therapeutics Inc (TRDA) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on US.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported TRDA revenue for 2024-12-31 was $210.8M. Net income was $65.6M. Revenue was up 63.4% from 2023-12-31 to 2024-12-31. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
Not investment advice. Open the RTX and TRDA stock pages for the full models.
Not investment advice.